Microsoft word - 280801-opioid equianalgesic chart _part b_.doc
PL Detail-Document #280801 −This PL Detail-Document accompanies the related article published in− PHARMACIST’S LETTER / PRESCRIBER’S LETTER Equianalgesic Dosing of Opioids for Pain Management Equianalgesic doses contained in this chart are approximate, and should be used only as a guideline. Dosing must be titrated to individual response. There is often incomplete cross-tolerance among these drugs. It is, therefore, recommended to begin with a 50% lower dose than the equianalgesic dose when changing drugs and then titrate to a safe/effective response.1,3,4,34 Dosing adjustments for renal or hepatic insufficiency, cytochrome P450 drug interactions, genetics, and other conditions or medications that affect drug metabolism, kinetics, or response may also be necessary.2,34,48,53 Also consider pain control at time of switch.4,5 In general, use cautious dosing for elderly or debilitated patients, and patients with renal or hepatic impairment.48 Some products have specific dosing recommendations for these populations (see footnotes).See our Opioid Conversion Algorithm for instructions on converting from one opioid to another. A website with an equianalgesic dose calculator is available at http://www.hopweb.org Drugf,i,k,L Equianalgesic Doses Approximate Usual Starting Dose (Opioid-Naïve (mg)1,3,4 Equianalgesic 24 hr Dose (Assumes Around-the- (Doses NOT Equianalgesic) Clock Dosing)g Parenteral Oral Parenteral Oral/Other Parenteral Oral/Other
Morphine (immediate-release tablets, oral
Extended-release morphine (Avinza [U.S.],
Copyright 2012 by Therapeutic Research Center
P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com
(PLDetail-Document #280801: Page 2 of 7) Drugf,i,k,L Equianalgesic Doses Approximate Usual Starting Dose (Opioid-Naïve (mg)1,3,4 Equianalgesic 24 hr Dose (Assumes Around-the- (Doses NOT Equianalgesic) Clock Dosing)g Parenteral Oral Parenteral Oral/Other Parenteral Oral/Other
(Hydromorph Contin [Canada]) Extended-release hydromorphone (Exalgo,
Oxycodone (e.g., Roxicodone [U.S.],
Oxecta [U.S.], Oxy IR [Canada], also in
pain)42,43 (Product labeling)
5-10 mg q 8-12 h14 or 5 mg q 4-6 h41 (chronic noncancer pain) (Guidelines)
Controlled-release oxycodone (OxyContin
5-10 mg q 4-12 h (chronic noncancer pain)14,41
(Opana ER [U.S.])c,q Hydrocodone (in Lortab [U.S.], Vicodin
Copyright 2012 by Therapeutic Research Center
P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com
(PLDetail-Document #280801: Page 3 of 7) Drugf,i,k,L Equianalgesic Doses Approximate Usual Starting Dose (Opioid-Naïve (mg)1,3,4 Equianalgesic 24 hr Dose (Assumes Around-the- (Doses NOT Equianalgesic) Clock Dosing)g Parenteral Oral Parenteral Oral/Other Parenteral Oral/Other
moderately severe pain)46 15-30 mg q 4-12 h (chronic noncancer pain)14,41
Controlled-release codeine (Codeine Contin NA
Methadone (Dolophine [U.S.], Metadol
For opioid-tolerant patients only.14 The conversion ratio of methadone
is highly variable depending on factors such as patient tolerance,
morphine dose, and length of dosing (short-term versus chronic dosing). Because the analgesic duration of action is shorter than the half-life, toxicity due to drug accumulation can occur with just a few doses.35 For conversion methods, see http://www.cancer.gov/cancertopics/pdq/supportivecare/pain/HealthProfessional/page3. Some experts recommend that only those with substantial experience with its use should prescribe methadone.39,55
Should be used for acute dosing only (short duration of action [2.5 to
3.5 hours]) and neurotoxic metabolite, normeperidine.1 Avoid in renal insufficiency and use caution in hepatic impairment and in the elderly (potential for toxicity due to accumulation of normeperidine).1,16-18 Seizures, myoclonus, tremor, confusion, and delirium may occur.1
Copyright 2012 by Therapeutic Research Center
P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com
(PLDetail-Document #280801: Page 4 of 7) Drugf,i,k,L Equianalgesic Doses Approximate Equianalgesic Usual Starting Dose (Opioid- (mg)1,3,4 24 hr Dose (Assumes Around- Naïve Adults) the-Clock Dosing)g (Doses NOT Equianalgesic) Parenteral Parenteral Oral/Other Parenteral Oral/Other
All noninjectable fentanyl products are for opioid-tolerant patients only. Do not convert mcg for mcg among fentanyl products (i.e., patch, transmucosal lozenge [Actiq (U.S.)], buccal tablet [Fentora (U.S.)], buccal film [Onsolis], nasal spray [Lazanda (U.S.)], sublingual tablet [Abstral]). See specific product labeling (U.S.: Drugs@FDA; Canada: Health Canada Drug Product Database) for dosing. Or, for U.S. products only, see our PL Chart, Fentanyl Products for Breakthrough Pain. Some experts use this conversion in cancer patients: oral morphine 60 mg total daily dose = 25 mcg/hr fentanyl patch. Round up or down based on patient factors and available patch sizes.56
NA = not available.
Most of the above oral opioids are available as generics. Exceptions (prices are AWP [U.S.]) include: Kadian ($6.63/30 mg cap), Avinza ($5.45/ 30 mg cap), Opana ($6.53/10 mg tab), Opana ER ($4.35/10 mg tab), OxyContin ($2.43/10 mg tab), Embeda ($4.98/20 mg cap), and Exalgo ($8.99/ 8 mg). As a comparison, generic morphine controlled-release = $1.69/30 mg tab.
a. Product labeling for hydromorphone recommends a starting dose of 0.2 mg to 1 mg IV every two to three hours (Canadian labeling: 2 mg IV
every four to six hours) as needed, or 2 mg to 4 mg orally every four to six hours as needed.8,15,20 An even lower oral starting dose (2 mg two or three times daily) has been recommended for chronic pain in opioid-naïve patients.14 Some institutions use even lower doses of parenteral hydromorphone (e.g., 0.2 mg to 0.5 mg every two hours as needed). One regimen starts opioid-naïve patients at 0.2 mg IV every two hours as needed for mild or moderate pain, with the option in moderate pain to give an extra 0.2 mg after 15 minutes if relief is inadequate after the first 0.2 mg dose. For severe pain, 0.5 mg IV every two hours as needed is used initially. In adults <65 years of age, the 0.5 mg dose can be repeated in 15 minutes if relief is inadequate, for a maximum of 1 mg in two hours.
b. Per the product labeling, convert to Exalgo 12 mg from oral codeine 200 mg, hydrocodone 30 mg, morphine 60 mg, oxycodone 30 mg,
oxymorphone 20 mg, or transdermal fentanyl 25 mcg/hr. After 50% dose reduction for incomplete cross-tolerance, reduce dose again by 50% for moderate renal impairment, and by 75% for severe renal or moderate hepatic impairment. Not for use in severe hepatic impairment.13 The Jurnistaproduct monograph recommends a 5:1 oral morphine:oral hydromorphone conversion ratio.19
c. Per the product labeling, oral oxymorphone 10 mg ER is approximately equivalent to hydrocodone 20 mg or oxycodone 20 mg.11 d. Dilaudid Canadian monograph recommends parenteral starting dose of 2 mg.20 See footnote “a” for additional information and precautions.
Copyright 2012 by Therapeutic Research Center
P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com
(PLDetail-Document #280801: Page 5 of 7)
e. No initial dose for Exalgo. For opioid-tolerant patients only.13 Initial Jurnista dose (opioid-naïve or <40 mg daily oral morphine equivalents) is
f. Tramadol (e.g., Ultram, Ralivia [Canada]), potency is about one-tenth that of morphine, similar to codeine.1 The maximum daily dose of
tramadol is 300 mg to 400 mg, depending on the product.22-28,36,37 See product labeling for dosing in elderly, or in renal or hepatic dysfunction.
g. Examples of doses seen in clinical practice, taking into account available dosage strengths. h. Labeling for some products (MS Contin [U.S.], Kadian, Jurnista [Canada]) recommends beginning treatment with an immediate-release
i. Tapentadol controlled-release (Nucynta CR, Canada) and oxycodone controlled-release exhibit comparable pain relief in a dose ratio of 5:1
(tapentadol:oxycodone).31 The maximum dose of tapentadol CR is 250 mg twice daily.31 No specific dose conversion is given for Nucynta (U.S.), Nucynta IR (Canada) and Nucynta ER (U.S.).32,33 Not for use in severe in renal or hepatic dysfunction.31-33,38
j. Some experts do not recommend for chronic pain in opioid-naïve patients.14 k. The initial dose of transdermal buprenorphine (Butrans) for patients taking less than 30 mg of oral morphine or equivalent per day is a 5 mcg/hr
patch applied once weekly (Canada: start with 5 mcg/hr patch in opioid-naïve patients, and 5-10 mcg/hr patch in patients taking up to 80 mg oral morphine equivalents per day). U.S.: When converting from 30 to 80 mg of morphine equivalents daily dose, first taper to 30 mg oral morphine equivalents, then start with the 10 mcg/hr patch.34 The maximum dose is 20 mcg/hr patch once weekly.34,47
L. Parenteral morphine 10 mg is approximately equal to parenteral pentazocine 60 mg, oral pentazocine 180 mg, parenteral butorphanol 2 mg, and
parenteral nalbuphine 10 mg.49 For buprenorphine transdermal patch (Butrans), see footnote “k.” The analgesic efficacy of these drugs is limited by a dose ceiling. Furthermore, the mixed agonists-antagonists (i.e., pentazocine, butorphanol, nalbuphine) are contraindicated for use in patients receiving an opioid agonist because they can precipitate withdrawal and increase pain. They also pose a risk of psychotomimetic effects.1
m. Reduce dose by 25% when switching from oral codeine phosphate to account for phosphate content of tablet.49 n. Analgesic efficacy limited by a dose ceiling.46,49 o. Relatively safe choice in renal or liver insufficiency.54,55 p. Relatively safe choice in renal or liver insufficiency.55 Clearance reduced by uremia.54 Do not start with patch in renal or liver failure.54 Watch
q. Opana ER has received a notice of compliance (June 2012) by Health Canada. At time of publication, it is not yet available on the Canadian
r. Start with an oral dose of 5 mg q 4-6 h for opioid-naïve elderly or opioid-naïve patients with renal or liver impairment.44
Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and Internet links in this article were current as of the date of publication.
Copyright 2012 by Therapeutic Research Center
P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com
(PLDetail-Document #280801: Page 6 of 7) Project Leader in preparation of this PL Detail-
17. Fulton CW. Limiting meperidine use in pain
Document: Melanie Cupp, Pharm.D., BCPS
management. Hosp Pharm 2001;36:1214,1217-8.
18. PL Detail-Document, Pharmacotherapy Choices for
Patients with Dementia. Pharmacist’s References Letter/Prescriber’s Letter. May 2008.
19. Product monograph for Jurnista. Janssen-Ortho Inc.
http://www.cancer.gov/cancertopics/pdq/supportivec
20. Product monograph for Dilaudid. Purdue Pharma.
are/pain/HealthProfessional/page3. (Accessed July
21. Product monograph for Kadian. Abbott Labs.
2. Pergolizzi J, Boger RH, Budd K, et al. Opioids and
the management of chronic severe pain in the
22. Product information for Ultram. PriCara. Raritan, NJ
elderly: consensus statement of an international
expert panel with focus on the six clinically most
23. Product information for Ultracet. PriCara. Raritan,
often used World Health Organization step III opioids
(buprenorphine, fentanyl, hydromorphone, 24. Product information for Ultram ER. PriCara. Raritan methadone, morphine, oxycodone). Pain Pract
25. Product monograph for Ralivia. Valeant Canada LP.
3. Agency for Healthcare Research and Quality.
Morbidity & mortality rounds on the web. Case &
26. Product monograph for Tramacet. Janssen-Ortho
commentary. Strassels SA. Miscalculated risk.
27. Product monograph for Zytram XL. Purdue Pharma.
http://webmm.ahrq.gov/case.aspx?caseID=132#table
28. Product monograph for Tridural. Labopharm Inc.
4. American Academy of Hospice and Palliative
Medicine. Key principles of opioid administration.
29. Product information for MS Contin. Purdue Pharma,
http://www.aahpm.org/pdf/equianalgesictable.pdf.
30. Product monograph for Hydromorph Contin. Purdue
5. American Academy of Hospice and Palliative
Pharma. Pickering, ON L1W 3W8. November 2010.
Medicine. Guidelines for prescribing opiates for
31. Product monograph for Nucynta CR. Janssen.
http://www.aahpm.org/pdf/guidelinesforopioids.pdf.
32. Product information for Nucynta ER. Janssen.
6. Product information for Kadian. Actavis Kadian LLC.
Product information for Nucynta. Janssen
Pharmaceuticals, Inc. Titusville, NJ 08560. July
Product information for Avinza. King
Pharmaceuticals, Inc. Bristol, TN 37620. July 2012.
34. FDA. Introduction for the FDA blueprint for
prescriber education for extended-release and long-
Pharma L.P. Stamford, CT 06901. June 2011.
9. Argoff CE, Silvershein DI. A comparison of long- and
http://www.fda.gov/downloads/Drugs/DrugSafety/Info
short-acting opioids for the treatment of chronic
rmationbyDrugClass/UCM277916.pdf. (Accessed
noncancer pain: tailoring therapy to meet patient
needs. Mayo Clin Proc 2009;84:602-12.
35. PL Detail Document, Methadone: Focus on Safety.
10. Product information for Opana injection. Endo
Pharmacist’s Letter/Prescriber’s Letter. September
Pharm. Chadds Ford, PA 19317. June 2006.
11. Product information for Opana ER. Endo Pharm.
Product monograph for Durela. Cipher
Pharmaceuticals Inc. Mississauga, ON L4W 4P1.
Product information for Embeda. King
Pharmaceuticals, Inc. Bristol, TN 37620. July 2012.
13. Product information for Exalgo. Mallinckrodt Brand
Pharmacists Association c2012. Ultram monograph
(October 2010). http://www.e-therapeutics.ca.
14. Manchikanti L, Abdi A, Atluri S, et al. American
Society of Interventional Pain Physicians (ASIPP)
38. Product monograph for Nucynta IR. Janssen Inc.
guidelines for responsible opioid prescribing in
chronic non-cancer pain: part 2-guidance. Pain
39. Centers for Disease Control and Prevention (CDC).
Vital signs: risk of overdose from methadone used
15. Product information for Dilaudid oral liquid and
for pain relief-United States, 1999-2010. MMWR
tablets. Abbott Laboratories. North Chicago, IL
Morb Mortal Wkly Rep 2012;61:493-7.
Prescribing information for morphine solution.
16. Product information for Demerol. Sanofi-aventis U.S.
Roxane Laboratories, Inc. Columbus, OH 43216.
Copyright 2012 by Therapeutic Research Center
P.O. Box 8190, Stockton, CA 95208 ~ Phone: 209-472-2240 ~ Fax: 209-472-2249
www.pharmacistsletter.com ~ www.prescribersletter.com ~ www.pharmacytechniciansletter.com
(PLDetail-Document #280801: Page 7 of 7)
41. Sundwall DN, Rolfs RT, Johnson E. Utah
(March 2012). http://www.e-therapeutics.ca.
Department of Health. Utah clinical guidelines on
prescribing opioids for treatment of pain. 2009.
http://www.dopl.utah.gov/licensing/forms/OpioidGuidl
Pharmacists Association c2012. MS IR monograph
(April 2011). http://www.e-therapeutics.ca.
Product information for Oxecta. King
Pharmaceuticals Inc. Bristol, TN 37620. June 2011.
52. Ballantyne JC, Mao J. Opioid therapy for chronic
43. Product monograph for Oxy IR. Purdue Pharma.
pain. N Engl J Med 2003;349:1943-53.
53. PL Detail-Document, Codeine Safety in Kids.
Product information for Opana. Endo
Pharmacist’s Letter/Prescriber’s Letter. June 2012.
Pharmaceuticals Inc. Chadds Ford, PA 19317.
54. Induru RR, Lagman RL. Managing cancer pain:
frequently asked questions. Cleve Clin J Med
45. Product information for Vicodin. Abbott Laboratories.
North Chicago, IL 60064. September 2011.
55. Carbonara GM. Opioids in patients with renal or
46. Product information for codeine sulfate tablets.
hepatic dysfunction. Practical Pain Management.
Roxane Laboratories, Inc. Columbus, OH 43228.
http://www.practicalpainmanagement.com/treatments
47. Product monograph for BuTrans. Purdue Pharma.
/pharmacological/opioids/opioids-patients-renal-
hepatic-dysfunction?page=0,0. (Accessed July 18,
48. PL Detail-Document, Opioids for Chronic Non-cancer
Pharmacist’s Letter/Prescriber’s Letter.
56. Skaer TL. Transdermal opioids for cancer pain.
Health Qual Life Outcomes 2006;4:24.
49. Product monograph for Codeine Contin. Purdue
Pharma. Pickering, ON L1W 3W8. November 2011.
eCPS [Internet]. Ottawa (ON): Canadian Pharmacists Association c2012. Opioids monograph
Cite this document as follows: PL Detail-Document, Equianalgesic Dosing of Opioids for Pain Management. Pharmacist’s Letter/Prescriber’s Letter. August 2012.
Evidence and Recommendations You Can Trust…
3120 West March Lane, P.O. Box 8190, Stockton, CA 95208 ~ TEL (209) 472-2240 ~ FAX (209) 472-2249
Copyright 2012 by Therapeutic Research Center
Subscribers to the Letter can get PLDetail-Documents, like this one,
on any topic covered in any issue by going to www.pharmacistsletter.com, www.prescribersletter.com, or www.pharmacytechniciansletter.com
Lanham Act False Advertising Litigation: A Potent Weapon in Contributed by Harold P. Weinberger, Jonathan M. Wagner and Tobias B. Jacoby, Kramer Levin More than ever before, pharmaceutical companies are suing competitors, alleging that a rival’s advertising for its prescription or over-the-counter drugs is false or misleading. These suits are an effective means to compete for market shar
D I E W E R T PA P I E R H A N D E L S B A N K Morning News 13. Juni 2013 Differenz Differenz Differenz US Börsen Overnight: Die Angst vor einem Ende des billigen Geldes drängt gegenwärtig auch an den US Börsen alles andere in den Hintergrund. Eine Mini-Erholung zum Handelsstart hielt am Mittwoch nicht lange, der Dow-Jones-Index schloss erstmals seit dem 5. Juni wie